Reducing Disease Activity in Multiple Sclerosis: Keeping Up with Recent Advances
- CME / AMA PRA Category 1 Credit™
- MOC / ABIM MOC Part 2 Credit
- MIPS Improvement Activity Under MACRA
Early diagnosis is key to improving outcomes in patients with MS. Initiating disease-modifying therapy (DMT) as soon as possible is essential to control disease symptoms, mitigate progression and prevent relapse, and minimize disease-related disability. An improved understanding of MS pathophysiology has revolutionized the DMT landscape, offering patients more than 15 approved therapies. However, difficulties remain in ensuring an accurate diagnosis and individualizing therapy for each patient, which may preclude patients from reaping the optimal benefits of therapy.
This activity, Reducing Disease Activity in Multiple Sclerosis: Keeping Up with Recent Advances, will provide clinicians with a concise, but comprehensive, review of approved DMTs for MS, illustrations of appropriate assessments, determinations of MS subtypes, identifications of prognostic factors, and determinations of patients’ risks for progression. It will also provide communication techniques and patient-engagement strategies that enable clinician/patient collaborations, improve treatment compliance, and enhance patient quality of life.
Welcome and Introduction
Current Evidence in MS Diagnosis
Integrating Evidence-based Treatment Goals into MS Management
Assessing Current and Emerging MS Therapies
This activity is intended for neurologists, MS specialists, and other healthcare professionals who manage patients with MS.
This program is designed to address the following NAM competencies: provide patient-centered care and employ evidence-based practice.
At the conclusion of this activity, participants should be able to:
- Integrate current evidence regarding criteria for diagnosing MS as early as possible in the course of disease
- Assess the benefits of initiating DMTs early to obtain achievable treatment goals
- Evaluate the clinical efficacy and safety of available and emerging DMTs to provide optimal personalized MS treatment selections
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and Rockpointe. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Penn State College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Information about CME credit for this activity is available by contacting Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference course #G6608-20-T.
Professor and Interim Chair
Department of Neurology Director, MS Comprehensive Care Center
Stony Brook University Medical Center
Stony Brook, NY
Dr. Coyle has held multiple leadership positions at the American Board of Psychiatry and Neurology, the American Academy of Neurology, the American Neurological Association, and the National MS Society. She has served as an adviser to the FDA and the Institute of Medicine. Dr. Coyle has received research funding from the National Institutes of Health (NIH) and the National MS Society, and she is actively engaged in studies to understand and treat MS and other neurological diseases.
Professor and Chairman of Neurology
Ruth Dunietz Kushner and Michael Jay Serwitz Chair in Multiple Sclerosis
Rutgers-New Jersey Medical School and
Robert Wood Johnson Medical School
New Brunswick, NJ
Dr. Dhib-Jalbut graduated Alpha-Omega-Alpha from the American University of Beirut in Lebanon and completed his neurology training at the University of Cincinnati. He then joined the Neuroimmunology Branch at the National Institutes of Health (NIH) in Bethesda, MD, where he trained as a Physician-Scientist in MS and Neuroimmunology. Dr. Dhib-Jalbut was a faculty member at the University of Maryland Department of Neurology between 1991 and 2003 and worked closely with Kenneth Johnson, Chair of the Department of Neurology at that time.
Dr. Dhib-Jalbut’s extramurally funded research includes how MS therapies work, biomarkers of treatment response in MS, and (more recently) how the gut microbiome contributes to the risk of MS. To date, he has contributed more than 130 manuscripts to the scientific literature. He has served as Associate Editor of the Journal of Neuroimmunology and the MS Journal and is a member of the Editorial Boards of Journal of Interferon and Cytokine Research, Cytokine, Multiple Sclerosis and Demyelinating Diseases, and the MS Journal. He has served on several national and international scientific committees, including Chairmanship of the Scientific Committee for the World Congress on MS in Montreal in 2008.
Dr. Dhib-Jalbut served as President of ACTRIMS and presided over the joint ACTRIMS/ ECTRIMS Congress held in Boston in 2014. He has been on the “Best Doctors in America” list since 2009 and has received several awards and recognitions, including an NIH-NINDS Mentoring Award, the Norman H. Edelman Clinical Science Mentoring Award at Rutgers, the Medical Excellence Award from the National MS Society, the Outstanding Medical Scientist Award from the Edward J. Ill Excellence in Medicine Foundation, and the Excellence in Research Award from the New Jersey Health Foundation.
ABIM MOC DESIGNATION STATEMENT
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. To receive MOC points, you MUST pass the post-test and complete the evaluation. For ABIM MOC points, your information will be shared with the ABIM through Penn State’s ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.
ABPN MOC DESIGNATION STATEMENT
MIPS CREDIT DESIGNATION
Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS).
The faculty reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Patricia K. Coyle, MD, FAAN, FANA: Consultant: Accordant, Alexion, Bayer, Biogen Idec, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, Mylan, Novartis, Serono, TG Therapeutics; Research: Actelion, Alkermes, Corrona, Genentech/Roche, MedDay, Novartis
Suhayl Dhib-Jalbut, MD: Consultant: Genzyme, Novartis; Research: Biogen Idec
Non-faculty Content Contributors Disclosures
Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Chad Williamson, MS, MBA, CMPP; Blair St. Amand: Nothing to disclose
Penn State faculty and staff involved in the development or review of this material have nothing to disclose.
INSTRUCTIONS FOR PARTICIPANTS AND OBTAINING CME/MIPS CREDIT/MOC POINTS
Jointly provided by Penn State College of Medicine and Rockpointe
This activity has been supported by educational grants from Biogen and Sanofi Genzyme.
Ensuring Optimal Integration of the GLP-1 Receptor Agonists: Review of the Latest Advances and Current Gaps in Care
Credits 1.00 (60 min)
Opioid Analgesics: Risk Evaluation and Mitigation Strategy (REMS) and the New FDA Blueprint
Credits 3.00 (3 hrs)